Lynch Emily, Falq Gregoire, Sun Chhorvy, Bunchhoeung Pharm D Tek, Huerga Helena, Loarec Anne, Dousset Jean-Phillipe, Marquardt Tonia, Paih Mickael Le, Maman David
Epicentre, 40 Rector St, New York, NY, 10006, USA.
Epicentre, Paris, France.
BMC Infect Dis. 2021 Feb 26;21(1):223. doi: 10.1186/s12879-021-05826-0.
Despite a dramatic reduction in HCV drug costs and simplified models of care, many countries lack important information on prevalence and risk factors to structure effective HCV services.
A cross-sectional, multi-stage cluster survey of HCV seroprevalence in adults 18 years and above was conducted, with an oversampling of those 45 years and above. One hundred forty-seven clusters of 25 households were randomly selected in two sets (set 1=24 clusters ≥18; set 2=123 clusters, ≥45). A multi-variable analysis assessed risk factors for sero-positivity among participants ≥45. The study occurred in rural Moung Ruessei Health Operational District, Battambang Province, Western Cambodia.
A total of 5098 individuals and 3616 households participated in the survey. The overall seroprevalence was 2.6% (CI95% 2.3-3.0) for those ≥18 years, 5.1% (CI95% 4.6-5.7) for adults ≥ 45 years, and 0.6% (CI95% 0.3-0.9) for adults 18-44. Viraemic prevalence was 1.9% (CI95% 1.6-2.1), 3.6% (CI95% 3.2-4.0), and 0.5% (CI95% 0.2-0.8), respectively. Men had higher prevalence than women: ≥18 years male seroprevalence was 3.0 (CI95% 2.5-3.5) versus 2.3 (CI95% 1.9-2.7) for women. Knowledge of HCV was poor: 64.7% of all respondents and 57.0% of seropositive participants reported never having heard of HCV. Risk factor characteristics for the population ≥45 years included: advancing age (p< 0.001), low education (higher than secondary school OR 0.7 [95% CI 0.6-0.8]), any dental or gum treatment (OR 1.6 [95% CI 1.3-1.8]), historical routine medical care (medical injection after 1990 OR 0.7 [95% CI 0.6-0.9]; surgery after 1990 OR 0.7 [95% CI0.5-0.9]), and historical blood donation or transfusion (blood donation after 1980 OR 0.4 [95% CI 0.2-0.8]); blood transfusion after 1990 OR 0.7 [95% CI 0.4-1.1]).
This study provides the first large-scale general adult population prevalence data on HCV infection in Cambodia. The results confirm the link between high prevalence and age ≥45 years, lower socio-economic status and past routine medical interventions (particularly those received before 1990 and 1980). This survey suggests high HCV prevalence in certain populations in Cambodia and can be used to guide national and local HCV policy discussion.
尽管丙型肝炎病毒(HCV)药物成本大幅降低且护理模式简化,但许多国家缺乏关于HCV流行率和风险因素的重要信息,难以构建有效的HCV服务体系。
对18岁及以上成年人进行了一项横断面、多阶段整群HCV血清流行率调查,对45岁及以上人群进行了过度抽样。在两组中随机选择了147个由25户家庭组成的群组(第1组=24个群组,年龄≥18岁;第2组=123个群组,年龄≥45岁)。多变量分析评估了45岁及以上参与者血清阳性的风险因素。该研究在柬埔寨西部马德望省蒙鲁塞伊农村卫生运营区进行。
共有5098人及3616户家庭参与了调查。18岁及以上人群的总体血清流行率为2.6%(95%置信区间2.3 - 3.0),45岁及以上成年人的血清流行率为5.1%(95%置信区间4.6 - 5.7),18 - 44岁成年人的血清流行率为0.6%(95%置信区间0.3 - 0.9)。病毒血症流行率分别为1.9%(95%置信区间1.6 - 2.1)、3.6%(95%置信区间3.2 - 4.0)和0.5%(95%置信区间0.2 - 0.8)。男性的流行率高于女性:18岁及以上男性血清流行率为3.0(95%置信区间2.5 - 3.5),女性为2.3(95%置信区间1.9 - 2.7)。对HCV的知晓率很低:所有受访者中有64.7%以及血清阳性参与者中有57.0%表示从未听说过HCV。45岁及以上人群的风险因素特征包括:年龄增长(p<0.001)、低教育水平(高于中学学历的比值比为0.7 [95%置信区间0.6 - 0.8])、任何牙科或牙龈治疗(比值比为1.6 [95%置信区间1.3 - 1.8])、既往常规医疗护理(1990年后的医疗注射比值比为0.7 [95%置信区间0.6 - 0.9];1990年后的手术比值比为0.7 [95%置信区间0.5 - 0.9])以及既往献血或输血(1980年后的献血比值比为0.4 [95%置信区间0.2 - 0.8];1990年后的输血比值比为0.7 [95%置信区间0.4 - 1.1])。
本研究提供了柬埔寨首个关于HCV感染的大规模普通成年人群流行率数据。结果证实了高流行率与年龄≥45岁、较低的社会经济地位以及过去的常规医疗干预(特别是1990年和1980年之前接受的干预)之间的联系。这项调查表明柬埔寨某些人群中HCV流行率较高,可用于指导国家和地方的HCV政策讨论。